Mario Berger Germany

• Advancing the Next Wave of Therapies in Chronic Kidney Disease
  DustinLittle Speaker United States
• Effects of Finerenone on Biomarkers: Mechanistic Insights From Proteomic Analyses in Clinical Trials
  MarioBerger Speaker mario.berger@bayer.comGermany
• Future Directions in CRM Care: Advancing Research and Therapeutic Innovation
  AntonioGarreta Rufas Speaker Germany
• Innovative Strategies for Clinical Trial Design in IgAN
  LokeshShah Speaker United States
• Improving Outcomes in Complement-mediated Kidney Diseases
  Marianne Silkjær Nielsen Speaker Switzerland
• Advancing Mechanistic Trials through Industry–Academia Collaboration: Insights from the REMODEL Trial
  ManuelMayrdorfer Speaker Denmark
• Why? When? How? How to Maximize Patient Outcomes From the Start of Dialysis
  PeterRutherford Speaker Switzerland

• Effect of a 12-week Intradialytic Cycling Intervention on Hemodialysis-induced Myocardial Stunning: A Multi-centre Randomized Controlled Trial
  ClaraBohm Speaker Canada
• TEACH-PD Cluster Randomized Controlled Trial: Targeted Education ApproaCH to improve Peritoneal Dialysis Outcomes
  JosephineChow Speaker Australia
• Effect of Finerenone on Circulating Biomarkers: A CONFIDENCE Analysis
  MarioBerger Speaker mario.berger@bayer.comGermany
• Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the CONFIDENCE Trial
  RajivAgarwal Speaker United States
• Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial
  RajivAgarwal Speaker United States
• Lowering-Hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double Blind Randomized Controlled Trial
  Naya Huang Speaker huangnaya@163.comChina